Luseogliflozin hydrate
Based on 1 publication(s) in Google Scholar
Luseogliflozin (TS 071) hydrate is a selective potent and orally active second-generation sodium-glucose co-transporter 2 (SGLT2) inhibitor with an IC50 of 2.26 nM. Luseogliflozin hydrate can be used for the research of type 2 diabetes mellitus (T2DM).
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 99.20%
- CAS 番号: 1152425-66-5
- 分子式: C23H32O7S
- 分子量:452.56
-
保管条件:
-20°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- プロトコル
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
HY-15516
SotagliflozinSGLT Inhibitor -
HY-17638
MizagliflozinSGLT1 Inhibitor -
HY-15461
ErtugliflozinSGLT2 Inhibitor -
HY-14902
TofogliflozinSGLT Inhibitor -
HY-14894A
Ipragliflozin L-ProlineSGLT Inhibitor -
HY-13414
RemogliflozinSGLT2 Inhibitor -
HY-109018
VelagliflozinSGLT Inhibitor -
HY-123797
KGA-2727SGLT1 Inhibitor -
HY-15461R
Ertugliflozin (Standard)SGLT2 Inhibitor -
HY-109144
EnavogliflozinSGLT-2 Inhibitor -
HY-17604
BexagliflozinSGLT2 Inhibitor -
HY-15461A
Ertugliflozin L-pyroglutamic acidSGLT2 Inhibitor
MedChemExpress（MCE）の使用を引用している文献 Luseogliflozin hydrate
More
生物活性
製品説明
IC50 & Target
|
SGLT2 |
体外実験
Luseogliflozin can increase beta cell proliferation through the activation of the FoxM1/PLK1/CENP-A pathway via humoral factors thats act in an insulin/IGF-1 receptor-independent manner. Luseogliflozin increases beta cell proliferation in OSI-906-treated mice[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:βIRKO, IRS1KO and IRS2KO beta cells
-
Concentration:100 nM
-
Incubation Time:24 and 48 hours
-
Result:Cell Viability Assay[2] Treating cells with serum from the OSI-906 (200 nM) or OSI-906+Luseogliflozin(100 nM) group led to significantly increased cell viability in the latter group in the control, IRS1KO, IRS2KO, as well as the insulin receptor (IR)-deficient βIRKO beta cells.
体内実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J male mice aged 8 weeks old[2]
-
Dosage:10 mg/kg/daily
-
Administration:Oral gavage; for 7 days between 08:00 and 09:00 hours
-
Result:Treatment significantly ameliorated the OSI-906 (45 mg/kg)-induced hyperglycaemia.
臨床実験
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
化学情報
-
CAS 番号 1152425-66-5
-
性状 Solid
-
分子量 452.56
-
分子式 C23H32O7S
-
Color White to off-white
-
SMILES
OC[C@@H](S1)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1C2=C(OC)C=C(C)C(CC3=CC=C(OCC)C=C3)=C2.O
-
別名
TS 071 hydrate
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
-20°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications (1)
-
Journal Impact Factor
-
Most Recent
純度とドキュメンテーション
-
データシート (273 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Anthony Markham,et al. Luseogliflozin: first global approval. Drugs. 2014 Jun;74(8):945-50. [Content Brief]
[2]. Jun Shirakawa,et al. Luseogliflozin increases beta cell proliferation through humoral factors that activate an insulin receptor- and IGF-1 receptor-independent pathway. Diabetologia. 2020 Mar;63(3):577-587. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Luseogliflozin hydrate 関連分類
HY-10449A 関連分類
Powered by Bioz